Literature DB >> 24847509

Management of patients with ST-segment elevation or non-ST-segment elevation acute coronary syndromes in cardiac rehabilitation centers.

Rona Reibis, Heinz Völler, Anselm Gitt, Christina Jannowitz, Martin Halle, David Pittrow, Steven Hildemann.   

Abstract

BACKGROUND: Current data on the management of patients in cardiac rehabilitation (CR) after an acute hospital stay due to ST-segment elevation or non-ST segment elevation acute coronary syndromes (STE-ACS or NSTE-ACS) are limited. We aimed to describe patient characteristics, risk factor management, and lipid target achievement of patients in CR in Germany and compare the 2 groups. HYPOTHESIS: With respect to the risk factor pattern and treatment effects during a CR stay, there are important differences between STE-ACS and NSTE-ACS patients.
METHODS: Comparison of 7950 patients by STE-ACS or NSTE-ACS status in the Transparency Registry to Objectify Guideline-Oriented Risk Factor Management registry (2010) who underwent an inpatient CR period of about 3 weeks.
RESULTS: STE-ACS patients compared to NSTE-ACS patients were significantly younger (60.5 vs 64.4 years, P < 0.0001), and had diabetes mellitus, hypertension, or any risk factor (exception: smoking) less often. At discharge, in STE-ACS compared to NSTE-ACS patients, the low-density lipoprotein cholesterol (LDL-C) <100 mg/dL goal was achieved by 75.3% and 76.2%, respectively (LDL-C <70 mg/dL by 27.7% and 27.4%), the high-density lipoprotein cholesterol goal of >50 mg/dL in women and >40 mg/dL in men was achieved by 49.3% and 49.0%, respectively, and the triglycerides goal of <150 mg/dl was achieved by 72.3% and 74.3%, respectively (all comparisons not significant). Mean systolic and diastolic blood pressure were 121/74 and 123/74 mm Hg, respectively (P < 0.0001 systolic, diastolic not significant). The maximum exercise capacity was 110 and 102 W, respectively (P < 0.0001), and the maximum walking distance was 581 and 451 meters, respectively (P value not significant).
CONCLUSIONS: Patients with STE-ACS and NSTE-ACS differed moderately in their baseline characteristics. Both groups benefited from the participation in CR, as their lipid profile, blood pressure, and physical fitness improved.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24847509      PMCID: PMC6649546          DOI: 10.1002/clc.22241

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

Review 1.  [Hypercholesterolemia - Where are we today? Where are we going?].

Authors:  A K Gitt; R Zahn
Journal:  Herz       Date:  2016-07-13       Impact factor: 1.443

2.  The role and outcome of cardiac rehabilitation program in patients with atrial fibrillation.

Authors:  Arwa Younis; Ella Shaviv; Eyal Nof; Ariel Israel; Anat Berkovitch; Ilan Goldenberg; Michael Glikson; Robert Klempfner; Roy Beinart
Journal:  Clin Cardiol       Date:  2018-09-20       Impact factor: 2.882

3.  Helicobacter pylori Seropositivity in Patients with Interleukin-1 Polymorphisms Is Significantly Associated with ST-Segment Elevation Myocardial Infarction.

Authors:  Noriaki Tabata; Daisuke Sueta; Tomonori Akasaka; Yuichiro Arima; Kenji Sakamoto; Eiichiro Yamamoto; Yasuhiro Izumiya; Megumi Yamamuro; Kenichi Tsujita; Sunao Kojima; Koichi Kaikita; Kazunori Morita; Kentaro Oniki; Junji Saruwatari; Kazuko Nakagawa; Seiji Hokimoto
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

4.  Fragmented QRS (fQRS) Complex Predicts Adverse Cardiac Events of ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention and Thrombolysis.

Authors:  Wei Xia; Xiao-Yan Feng
Journal:  Med Sci Monit       Date:  2018-07-05

5.  Heart rate recovery is useful for evaluating the recovery of exercise tolerance in patients with heart failure and atrial fibrillation.

Authors:  Seiya Tanaka; Taro Miyamoto; Yusuke Mori; Takashi Harada; Hiromi Tasaki
Journal:  Heart Vessels       Date:  2021-03-30       Impact factor: 2.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.